News & Events
CHROMATIN CEO AND FOUNDER TO ADDRESS POLICY MAKERS ON ADVANCING CROP PRODUCTIVITY
Washington, D.C., Seminar Hosted by The Howard Hughes Medical Institute (HHMI) and the Center for Strategic and International Studies (CSIS)
WASHINGTON, D.C. -- Chromatin Inc. announced today that Mich Hein, president and CEO, and Daphne Preuss, developer of the company's mini-chromosome technology, will speak at a luncheon seminar hosted by the The Howard Hughes Medical Institute (HHMI) and the Center for Strategic and International Studies (CSIS) on February 5, 2004.
The seminar, titled "Frontier Plant Biotechnology: Advancing Crop Productivity and Market Potential," will be held at the American Association for the Advancement of Science (AAAS) Auditorium, 1200 New York Avenue, NW, Washington, D.C., from noon to 2:00 p.m
Hein and Preuss will be joined by Anthony J. (Tony) Cavalieri, Ph.D., former vice president and director, Trait & Technology Development, Pioneer Hi-Bred International, Inc., a DuPont company, in discussing how knowledge derived in academic and industrial laboratories is leading to the development of crops with enhanced productivity, nutrition, and pharmaceutical and industrial uses.
A special focus will be challenges associated with moving laboratory research breakthroughs into the marketplace - conflicts of interest, intellectual property rights, venture capital requirements, legal and other technology transfer complexities.
Daphne Preuss, Ph.D. is a HHMI investigator and University of Chicago professor who developed Chromatin's mini-chromosome technology and founded the company.
This is one of a seminar series on biotechnology and public policy co-hosted by the Center for Strategic and International Studies and the Howard Hughes Medical Institute. Speakers' biographies, research descriptions and other relevant information may be found on the HHMI, Chromatin and Pioneer websites. Reports on previous sessions may be found on the CSIS website.
About Chromatin
Chromatin, Inc., develops and markets novel proprietary technology that enables entire chromosomes to be designed and incorporated into plant cells. These engineered chromosomes make it possible for the first time to simultaneously introduce multiple genes into a plant cell while maintaining precise control of gene expression. Chromatin is employing these new genetic tools to design and market products that confer commercially valuable traits in plants, including improved nutritional and health characteristics, and can be used for industrial, agricultural and pharmaceutical product development.
Chromatin's investors include Burrill & Co., Foragen Technology Management, Venture Investors, Unilever Technology Ventures, Illinois Ventures; in addition, significant support has been provided by the Advanced Technology Program (ATP), the Department of Energy (DOE) and the National Institutes of Health (NIH).
For more information go to www.chromatininc.com.